EZH2 and metabolic dysfunction-associated steatohepatitis: In non-alcoholic steatohepatitis-associated HCC (NASH-HCC), YTHDF1 was targeted by lipid nanoparticles (LNPs)-encapsulated small-interfering YTHDF1, which can promote antitumor immunity by suppressing EZH2-IL-6 axis (175).